Key molecular events in the progression of melanoma are poorly understood, which prevents the development of targeted therapies. The access to a highly sensible genomic platform and collection of frozen melanomas allowed European researchers to conduct the first large genomic study of primary melanomas.
Go to Previous Page
Go to Next Page